A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Trial to Evaluate the Efficacy and Safety of TQH2722 Injection in the Treatment of Moderate to Severe Atopic Dermatitis in Subjects
Latest Information Update: 30 Aug 2024
At a glance
- Drugs TQH 2722 (Primary)
- Indications Atopic dermatitis
- Focus Therapeutic Use
- Sponsors Chia Tai Tianqing Pharmaceutical Group
Most Recent Events
- 30 Aug 2024 New trial record